Since the MOSAIC study was published in 2004, no
other new agents have been shown to improve colon
cancer outcomes. For example, although highly effective
in the metastatic setting, Irinotecan chemotherapy has
failed in three large randomised adjuvant studies - the
EORTC PETACC-3, ACCORD and CALGB 89803